Haïg Nigolian1, Camillo Ribi2, Delphine S Courvoisier3, Sabrina Pagano4,5, Montserrat Alvarez1, Marten Trendelenburg6, Uyen Huynh-Do7, Nicolas Vuilleumier4,5, Jean-Michel Dayer8, Carlo Chizzolini1, Pascale Roux-Lombard1. 1. Division of Immunology and Allergy, University Hospital and School of Medicine, Geneva, Switzerland. 2. Division of Immunology and Allergy, University Hospital of Lausanne and Lausanne University, Lausanne, Switzerland. 3. Division of Rheumatology, University Hospital and School of Medicine, Switzerland. 4. Division of Laboratory Medicine, Diagnostic Department, Switzerland. 5. Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland. 6. Laboratory for Clinical Immunology, Department of Biomedicine and Division of Internal Medicine, University Hospital of Basel, Basel, Switzerland. 7. Division of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland. 8. Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Abstract
OBJECTIVES: Apolipoprotein A-1 (ApoA-1) is a protein fraction of the high-density lipoproteins with anti-inflammatory and antioxidant properties that play a major role in reverse cholesterol transport. The presence of anti-ApoA-1 IgG has been reported in SLE to be variably associated with disease activity or cardiovascular events (CVEs). We assessed the clinical performance of anti-ApoA-1 IgG and of antibodies directed against its immunodominant F3L1 peptide (F3L1 IgG) in a well-characterized Swiss SLE cohort study. METHODS: A total of 354 biological samples and interviews from 176 individuals were studied. SLEDAI, clinical characteristics, anamnestic CVEs and therapy details were recorded. Sera were tested for the presence of anti-ApoA-1 IgG, anti-F3L1 IgG, anti-dsDNA IgG and aPL. RESULTS: Anti-ApoA-1 and anti-F3L1 IgG positivity was associated with higher SLEDAI, mostly due to concomitant positivity of dsDNA IgG and low complement. Variations in time of anti-ApoA-1 IgG correlated positively with variations of anti-dsDNA IgG and inversely to variations of C3 levels. No cross-reactivity was found between anti-ApoA-1 and anti-dsDNA IgG. Positivity for anti-Apo-A1 IgG was more frequent in individuals receiving 10 mg/day or more of prednisone. We did not find any significant association between anti-ApoA-1 IgG positivity and CVEs. CONCLUSION: Anti-ApoA-1 and anti-F3L1 IgG in SLE correlate strongly with laboratory markers of activity, particularly with the presence and titre of dsDNA IgG. These results confirm and extend previous findings and support the use of anti-ApoA1 IgG in the clinical setting. Their role in CVEs deserves further investigation.
OBJECTIVES:Apolipoprotein A-1 (ApoA-1) is a protein fraction of the high-density lipoproteins with anti-inflammatory and antioxidant properties that play a major role in reverse cholesterol transport. The presence of anti-ApoA-1 IgG has been reported in SLE to be variably associated with disease activity or cardiovascular events (CVEs). We assessed the clinical performance of anti-ApoA-1 IgG and of antibodies directed against its immunodominant F3L1 peptide (F3L1 IgG) in a well-characterized Swiss SLE cohort study. METHODS: A total of 354 biological samples and interviews from 176 individuals were studied. SLEDAI, clinical characteristics, anamnestic CVEs and therapy details were recorded. Sera were tested for the presence of anti-ApoA-1 IgG, anti-F3L1 IgG, anti-dsDNA IgG and aPL. RESULTS: Anti-ApoA-1 and anti-F3L1 IgG positivity was associated with higher SLEDAI, mostly due to concomitant positivity of dsDNA IgG and low complement. Variations in time of anti-ApoA-1 IgG correlated positively with variations of anti-dsDNA IgG and inversely to variations of C3 levels. No cross-reactivity was found between anti-ApoA-1 and anti-dsDNA IgG. Positivity for anti-Apo-A1 IgG was more frequent in individuals receiving 10 mg/day or more of prednisone. We did not find any significant association between anti-ApoA-1 IgG positivity and CVEs. CONCLUSION: Anti-ApoA-1 and anti-F3L1 IgG in SLE correlate strongly with laboratory markers of activity, particularly with the presence and titre of dsDNA IgG. These results confirm and extend previous findings and support the use of anti-ApoA1 IgG in the clinical setting. Their role in CVEs deserves further investigation.
Authors: Kirsty E Waddington; George A Robinson; Leda Coelewij; Elvira Chocano; Thomas McDonnell; Filipa Farinha; Junjie Peng; Pierre Dönnes; Edward Smith; Sara Croca; Jyoti Bakshi; Maura Griffin; Andrew Nicolaides; Anisur Rahman; Elizabeth C Jury; Ines Pineda-Torra Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-04 Impact factor: 10.514